Please check your internet connection and try again.
## Meftal Spas
### Overview
Meftal Spas is a combination medication containing **mefenamic acid**, a nonsteroidal anti-inflammatory drug (NSAID), and **dicyclomine hydrochloride**, an anticholinergic antispasmodic.
### Primary Indications
* Relief of abdominal pain and cramps associated with irritable bowel syndrome (IBS) and other gastrointestinal spasms.
* Management of mild to moderate pain, particularly when associated with inflammatory conditions.
### Adult Dosing
* **Abdominal Pain/Spasms:** Typically 1 tablet (250 mg mefenamic acid / 20 mg dicyclomine) every 8 hours as needed.
* **Pain Management:** Typically 1 tablet every 8 hours as needed.
* **Maximum Dose:** Do not exceed 4 tablets in a 24-hour period. Duration of use for symptomatic relief of IBS should not exceed 2 weeks.
### Pediatric Dosing
* Dosing has not been established for children under 12 years of age. Use in this population is generally not recommended due to safety concerns with both components, especially the anticholinergic effects of dicyclomine.
### Dose Adjustments
* **Renal Impairment:** Use with caution. Mefenamic acid can cause renal adverse effects. Dose reduction may be necessary, and close monitoring is advised. Specific guidelines are lacking; consult renal dosing resources.
* **Hepatic Impairment:** Use with caution. Mefenamic acid can affect liver function. Close monitoring is advised. Specific guidelines are lacking; consult hepatic dosing resources.
* **Elderly:** Increased risk of adverse effects, particularly gastrointestinal bleeding, renal events, and cardiovascular events. Use the lowest effective dose for the shortest possible duration.
### Contraindications
* Hypersensitivity to mefenamic acid, dicyclomine, or any component of the formulation.
* Patients with a history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
* Severe renal impairment (CrCl < 30 mL/min).
* Severe hepatic impairment.
* Severe ulcerative colitis or toxic megacolon.
* Gastrointestinal bleeding or perforation.
* Obstructive uropathy.
* Myasthenia gravis.
* Glaucoma (especially narrow-angle).
* Tachycardia.
* Uncontrolled heart failure.
* Infants less than 6 months of age (due to anticholinergic effects).
### Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, abdominal pain, constipation, dizziness, dry mouth, blurred vision, drowsiness.
* **Serious:**
* **Gastrointestinal:** Serious GI bleeding, ulceration, and perforation (may occur at any time, with or without warning symptoms, and can be fatal).
* **Cardiovascular:** Increased risk of myocardial infarction, stroke, and related deaths.
* **Renal:** Acute kidney injury, interstitial nephritis, papillary necrosis.
* **Hepatic:** Elevated liver enzymes, hepatitis, jaundice.
* **Hematologic:** Anemia, leukopenia, thrombocytopenia.
* **Neurologic:** Confusion, hallucinations, seizures.
* **Ophthalmic:** Blurred vision, increased intraocular pressure, angle-closure glaucoma.
* **Other:** Allergic reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis.
### Key Drug Interactions
* **Anticoagulants (e.g., warfarin):** Increased risk of bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Selective Serotonin Reuptake Inhibitors (SSRIs) & Serotonin Norepinephrine Reuptake Inhibitors (SNRIs):** Increased risk of GI bleeding.
* **Other NSAIDs & Aspirin:** Increased risk of GI toxicity, renal toxicity, and bleeding.
* **Diuretics & Antihypertensives (e.g., ACE inhibitors, ARBs):** Reduced antihypertensive effect and increased risk of renal impairment.
* **Lithium:** Increased serum lithium levels.
* **Methotrexate:** Increased methotrexate toxicity.
* **Anticholinergics:** Additive anticholinergic effects.
* **Antacids/Adsorbents:** May decrease absorption of dicyclomine.
### Monitoring
* **GI Bleeding:** Monitor for signs and symptoms (e.g., melena, hematemesis, abdominal pain).
* **Renal Function:** Monitor creatinine, BUN, and urine output, especially in patients with pre-existing renal disease or those receiving other nephrotoxic agents.
* **Hepatic Function:** Monitor liver enzymes (AST, ALT) in patients with pre-existing liver disease or those receiving long-term therapy.
* **Blood Pressure:** Monitor blood pressure, particularly with concomitant use of antihypertensives.
* **Signs of Anticholinergic Toxicity:** Monitor for dry mouth, blurred vision, urinary retention, constipation, and CNS effects.
### Clinical Pearls
* Meftal Spas should be used at the lowest effective dose for the shortest duration necessary to control symptoms.
* Consider the risks of NSAID use (GI, cardiovascular, renal) in all patients, especially the elderly and those with pre-existing conditions.
* Anticholinergic side effects can be more pronounced in the elderly.
* Avoid concurrent use with other NSAIDs or aspirin unless specifically indicated and monitored.
* Patients should be advised to report any signs of bleeding, severe stomach pain, or changes in vision immediately.
***
*This information is for educational purposes only and does not substitute for professional medical advice. Always verify current prescribing information and consult with a healthcare professional before making any decisions about drug therapy.*
